Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease | Cardiology | JAMA Cardiology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.236.187.155. Please contact the publisher to request reinstatement.
1.
Baigent  C, Keech  A, Kearney  PM,  et al; Cholesterol Treatment Trialists’ (CTT) Collaborators.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.  Lancet. 2005;366(9493):1267-1278.PubMedGoogle ScholarCrossref
2.
Fulcher  J, O’Connell  R, Voysey  M,  et al; Cholesterol Treatment Trialists’ (CTT) Collaboration.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.  Lancet. 2015;385(9976):1397-1405.PubMedGoogle ScholarCrossref
3.
Arnold  SV, Spertus  JA, Tang  F,  et al.  Statin use in outpatients with obstructive coronary artery disease.  Circulation. 2011;124(22):2405-2410.PubMedGoogle ScholarCrossref
4.
Borden  WB, Redberg  RF, Mushlin  AI, Dai  D, Kaltenbach  LA, Spertus  JA.  Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention.  JAMA. 2011;305(18):1882-1889.PubMedGoogle ScholarCrossref
5.
Drozda  JP  Jr, Ferguson  TB  Jr, Jneid  H,  et al.  2015 ACC/AHA focused update of secondary prevention lipid performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.  J Am Coll Cardiol. 2016;67(5):558-587.PubMedGoogle ScholarCrossref
6.
Kumar  A, Fonarow  GC, Eagle  KA,  et al; REACH Investigators.  Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.  Crit Pathw Cardiol. 2009;8(3):104-111.PubMedGoogle ScholarCrossref
7.
Maddox  TM, Chan  PS, Spertus  JA,  et al.  Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: insights from the NCDR (National Cardiovascular Data Registry).  J Am Coll Cardiol. 2014;63(6):539-546.PubMedGoogle ScholarCrossref
8.
Kuklina  EV, Yoon  PW, Keenan  NL.  Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006.  JAMA. 2009;302(19):2104-2110.PubMedGoogle ScholarCrossref
9.
Kaufman  HW, Blatt  AJ, Huang  X, Odeh  MA, Superko  HR.  Blood cholesterol trends 2001-2011 in the United States: analysis of 105 million patient records.  PLoS One. 2013;8(5):e63416.PubMedGoogle ScholarCrossref
10.
Foody  JM, Sajjan  SG, Hu  XH,  et al.  Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients.  J Clin Lipidol. 2010;4(2):126-132.PubMedGoogle ScholarCrossref
11.
Arnold  SV, Spertus  JA, Masoudi  FA,  et al.  Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction.  J Am Coll Cardiol. 2013;62(19):1791-1801.PubMedGoogle ScholarCrossref
12.
Muntner  P, Levitan  EB, Brown  TM,  et al.  Trends in the prevalence, awareness, treatment and control of high low density lipoprotein-cholesterol among United States adults from 1999-2000 through 2009-2010.  Am J Cardiol. 2013;112(5):664-670.PubMedGoogle ScholarCrossref
13.
Cannon  CP, Braunwald  E, McCabe  CH,  et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 Investigators.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes.  N Engl J Med. 2004;350(15):1495-1504.PubMedGoogle ScholarCrossref
14.
Cannon  CP, Steinberg  BA, Murphy  SA, Mega  JL, Braunwald  E.  Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy.  J Am Coll Cardiol. 2006;48(3):438-445.PubMedGoogle ScholarCrossref
15.
LaRosa  JC, Grundy  SM, Waters  DD,  et al; Treating to New Targets (TNT) Investigators.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease.  N Engl J Med. 2005;352(14):1425-1435.PubMedGoogle ScholarCrossref
16.
Nissen  SE, Tuzcu  EM, Schoenhagen  P,  et al; REVERSAL Investigators.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.  JAMA. 2004;291(9):1071-1080.PubMedGoogle ScholarCrossref
17.
Nicholls  SJ, Ballantyne  CM, Barter  PJ,  et al.  Effect of two intensive statin regimens on progression of coronary disease.  N Engl J Med. 2011;365(22):2078-2087.PubMedGoogle ScholarCrossref
18.
Stone  NJ, Robinson  JG, Lichtenstein  AH,  et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.  J Am Coll Cardiol. 2014;63(25, pt B):2889-2934.PubMedGoogle ScholarCrossref
19.
Lloyd-Jones  DM, Goff  DC  Jr, Stone  NJ.  Guidelines for cardiovascular risk assessment and cholesterol treatment.  JAMA. 2014;311(21):2235.PubMedGoogle ScholarCrossref
20.
Downs  JR, O’Malley  PG.  Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 US Department of Veterans Affairs and US Department of Defense clinical practice guideline.  Ann Intern Med. 2015;163(4):291-297.PubMedGoogle ScholarCrossref
21.
Smith  MEB, Lee  NJ, Haney  E, Carson  S. Drug class review: HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin: final report update 5. In:  Drug Class Reviews. Portland: Oregon Health & Science University; 2009.
22.
Andrade  SE, Kahler  KH, Frech  F, Chan  KA.  Methods for evaluation of medication adherence and persistence using automated databases.  Pharmacoepidemiol Drug Saf. 2006;15(8):565-567. PubMedGoogle ScholarCrossref
23.
Virani  SS, Woodard  LD, Akeroyd  JM, Ramsey  DJ, Ballantyne  CM, Petersen  LA.  Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines.  Clin Cardiol. 2014;37(11):653-659.PubMedGoogle ScholarCrossref
24.
Virani  SS, Woodard  LD, Chitwood  SS,  et al.  Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease.  Am Heart J. 2011;162(4):725-732.e1. PubMedGoogle ScholarCrossref
25.
Virani  SS, Woodard  LD, Wang  D,  et al.  Correlates of repeat lipid testing in patients with coronary heart disease.  JAMA Intern Med. 2013;173(15):1439-1444.PubMedGoogle ScholarCrossref
26.
Maddox  TM, Borden  WB, Tang  F,  et al.  Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry.  J Am Coll Cardiol. 2014;64(21):2183-2192.PubMedGoogle ScholarCrossref
27.
Rosenson  RS, Kent  ST, Brown  TM,  et al.  Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease.  J Am Coll Cardiol. 2015;65(3):270-277.PubMedGoogle ScholarCrossref
28.
Strandberg  TE, Kolehmainen  L, Vuorio  A.  Evaluation and treatment of older patients with hypercholesterolemia: a clinical review.  JAMA. 2014;312(11):1136-1144.PubMedGoogle ScholarCrossref
29.
Miedema  MD, Lopez  FL, Blaha  MJ,  et al.  Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US cohort: the Atherosclerosis Risk in Communities study cohort.  JAMA Intern Med. 2015;175(1):138-140.PubMedGoogle ScholarCrossref
30.
Ko  DT, Mamdani  M, Alter  DA.  Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox.  JAMA. 2004;291(15):1864-1870.PubMedGoogle ScholarCrossref
31.
Rathore  SS, Mehta  RH, Wang  Y, Radford  MJ, Krumholz  HM.  Effects of age on the quality of care provided to older patients with acute myocardial infarction.  Am J Med. 2003;114(4):307-315.PubMedGoogle ScholarCrossref
32.
Redelmeier  DA, Tan  SH, Booth  GL.  The treatment of unrelated disorders in patients with chronic medical diseases.  N Engl J Med. 1998;338(21):1516-1520.PubMedGoogle ScholarCrossref
Original Investigation
January 2017

Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease

Author Affiliations
  • 1Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, California
  • 2Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas
  • 3Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, Texas
  • 4Division of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, California
JAMA Cardiol. 2017;2(1):47-54. doi:10.1001/jamacardio.2016.4052
Key Points

Question  Is intensity of statin therapy associated with all-cause mortality in a large national sample of patients in the Veterans Affairs health care system with atherosclerotic cardiovascular disease?

Findings  In this cohort study of 509 766 patients with atherosclerotic cardiovascular disease, there was an inverse association between intensity of statin therapy and mortality, with the greatest 1-year mortality reductions for patients receiving high-intensity statins. These findings were consistent across multiple subgroups, including adults older than 75 years.

Meaning  Maximally tolerated doses of high-intensity statins may confer a survival advantage to patients with atherosclerotic cardiovascular disease, including older adults.

Abstract

Importance  High-intensity statin therapy is recommended for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD). Nevertheless, statin therapy in general, and high-intensity statin therapy in particular, is underused in patients with established ASCVD.

Objective  To determine the association between all-cause mortality and intensity of statin therapy in the Veterans Affairs health care system.

Design, Setting, and Participants  A retrospective cohort analysis was conducted of patients aged 21 to 84 years with ASCVD treated in the Veterans Affairs health care system from April 1, 2013, to April 1, 2014. Patients who were included had 1 or more International Classification of Diseases, Ninth Revision codes for ASCVD on 2 or more different dates in the prior 2 years.

Exposures  Intensity of statin therapy was defined by the 2013 American College of Cardiology/American Heart Association guidelines, and use was defined as a filled prescription in the prior 6 months. Patients were excluded if they were taking a higher statin dose in the prior 5 years.

Main Outcomes and Measures  The primary outcome was death from all causes adjusted for the propensity to receive high-intensity statins.

Results  The study sample included 509 766 eligible adults with ASCVD at baseline (mean [SD] age, 68.5 [8.8] years; 499 598 men and 10 168 women), including 150 928 (29.6%) receiving high-intensity statin therapy, 232 293 (45.6%) receiving moderate-intensity statin therapy, 33 920 (6.7%) receiving low-intensity statin therapy, and 92 625 (18.2%) receiving no statins. During a mean follow-up of 492 days, there was a graded association between intensity of statin therapy and mortality, with 1-year mortality rates of 4.0% (5103 of 126 139) for those receiving high-intensity statin therapy, 4.8% (9703 of 200 709) for those receiving moderate-intensity statin therapy, 5.7% (1632 of 28 765) for those receiving low-intensity statin therapy, and 6.6% (4868 of 73 728) for those receiving no statin (P < .001). After adjusting for the propensity to receive high-intensity statins, the hazard ratio for mortality was 0.91 (95% CI, 0.88-0.93) for those receiving high- vs moderate-intensity statins. The magnitude of benefit of high- vs moderate-intensity statins was similar, for an incident cohort hazard ratio of 0.93 (95% CI, 0.85-1.01). For patients aged 76 to 84 years, the hazard ratio was 0.91 (95% CI, 0.87-0.95). Patients treated with maximal doses of high-intensity statins had lower mortality (hazard ratio, 0.90; 95% CI, 0.87-0.94) compared with those receiving submaximal doses.

Conclusions and Relevance  We found a graded association between intensity of statin therapy and mortality in a national sample of patients with ASCVD. High-intensity statins were associated with a small but significant survival advantage compared with moderate-intensity statins, even among older adults. Maximal doses of high-intensity statins were associated with a further survival benefit.

×